Document text
Principal Investigator: Chester Edward Markwalter
Organization: OPTIMEOS LIFE SCIENCES, INC.
Fiscal Year: 2024
Award: $300,000
Funding agency: National Institute of Allergy and Infectious Diseases
In this Phase I SBIR, Optimeos will develop an off-the-shelf, in situ CAR-Treg therapy through the
nanoparticle-mediated delivery of a CAR-FoxP3 construct to CD4+ T cells as a treatment for transplant rejection.
We envision an off-the-shelf therapy that reduces the healthcare costs and high burden of adoptive cell therapies.
Ex vivo Chimeric Antigen Receptor Regulatory T cells (CAR-Treg) are currently under development for transplant
rejection and other autoimmune diseases, building on the dramatic clinical benefits in cancer from CAR-T effector
cells. The first ex vivo CAR-Treg has now moved into the clinic in the STEADFAST trial for kidney transplant
patients. CAR-Treg cells directed against the HLA antigen could provide immune tolerance after transplantation
without global immune suppression. This will decrease the incidence or severity of transplant rejection in well-
matched transplants, and allow more transplants due to less stringent HLA matching requirements.
We propose generation of CAR-Treg cells in situ to overcome the complex manufacturing of current
approaches. Ex vivo CAR-T cells, both regulatory and effector, require labor-intensive, weeks-long processes
starting from the patient’s own cells. These therapies can cost $400,000 or more, which will prove prohibitive for
many non-oncologic diseases. Our off-the-shelf CAR-Treg therapy will use nanoparticle-encapsulated mRNA
encoding both the CAR, to induce antigen specificity, and FoxP3, to drive the regulatory phenotype. We will
employ anti-CD4 antibodies as our targeting moiety to reach the desired population after IV administration.
Our Coated Inverse NanoCarriers (CINCs) encapsulate mRNA in a polymer/lipid hybrid structure that
minimizes inflammation and enhances targeted delivery by providing stable attachment of the targeting ligand.
The targeting capabilities of CINCs will allow us to reach peripheral, splenic, and lymphatic T cells while
minimizing non-specific liver clearance. The immune-silent CINC platform permits repeat dosing and minimizes
inflammation, a profile that will be essential for in situ CAR-Treg. Over two aims in this proposal, we will select
our lead CINC formulation and design the mRNA cargo to generate CAR-Treg cells in vivo.
Specific Aim 1: Target CINCs to CD4+ T cells in vivo. We will select the CINC formulation that exhibits
both robust transfection of primary human T cells in vitro and high specificity in vivo. We expect to achieve 15x
enhancement in delivery to peripheral CD4+ T cells with a >3x reduction in liver delivery.
Specific Aim 2: Create and validate mRNA constructs for CAR-Treg generation. Our mRNA
sequence design will employ a CAR for HLA-A2 with FoxP3 on the same construct to ensure antigen-specific
suppressive function. After in vitro functional validation, we expect a humanized mouse study conducted with
our lead CINC formulation to show an expression peak of 5% CAR+ cells within the CD4+ compartment.
In Phase II, we plan to demonstrate efficacy in a skin transplant model, bringing a safe, off-the-shelf
therapy closer to addressing diseases that affect nearly 50 million Americans.
Terms: <Address><Adoptive Cell Transfers><Affect><Allogenic><American><Antibodies><Antigens><Autoimmune><Autoimmune Diseases><Autoregulation><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cancers><Caring><Cell Body><Cell Function><Cell Physiology><Cell Process><Cell Therapy><Cells><Cellular Function><Cellular Physiology><Cellular Process><Clinic><Clinical><Complex><Cy5><Dermatoplasties><Dermatoplasty><Development><Disease><Disorder><Dose><Encapsulated><Ensure><Exhibits><FOXP3><FOXP3 gene><Face><Forkhead Box P3><Formulation><Generations><Genetic><Graft Rejection><GvHD><HL-A Antigens><HLA Antigens><HLA Class I Histocompatibility Antigen, A-2 Alpha Chain><HLA-A Class I Antigen 2><HLA-A Histocompatibility Type Antigen 2><HLA-A2><HLA-A2 Antigen><Health Care Costs><Health Costs><Healthcare Costs><Homeostasis><Homologous Wasting Disease><Human><Human Leukocyte Antigens><Hybrids><Immune><Immune Tolerance><Immune response><Immunes><Immunochemical Immunologic><Immunologic><Immunologic Tolerance><Immunological><Immunological response><Immunologically><Immunologics><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><In Situ><In Vitro><Incidence><Inflammation><Inflammatory><Instruction><JM2><Kidney Grafting><Kidney Transplantation><Kidney Transplants><Label><Lead><Leukocyte Antigens><Ligands><Lipids><Liver><Lymphatic><Major Histocompatibility Complex, Class I, A2 Antigen><Malignant Neoplasms><Malignant Tumor><Marketing><Mediating><Medical><Messenger RNA><Mice><Mice Mammals><Modeling><Modern Man><Monitor><Murine><Mus><OKT3 antigen><Oncology><Oncology Cancer><PBMC><Patients><Pb element><Performance><Peripheral><Peripheral Blood Mononuclear Cell><Phase><Phenotype><Physiological Homeostasis><Play><Polymers><Population><Position><Positioning Attribute><Process><Production><Property><Regimen><Regulatory T-Lymphocyte><Renal Grafting><Renal Transplantation><Renal Transplants><Risk><Role><Runt Disease><SBIR><SCURFIN><Safety><Severities><Skin Transplantation><Small Business Innovation Research><Small Business Innovation Research Grant><Specificity><Structure><Subcellular Process><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell response><T cell targeted therapeutics><T cell therapy><T cells for CAR><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><T-cell therapeutics><T-cell transfer therapy><T3 Antigens><T3 Complex><T3 molecule><T4 Cells><T4 Lymphocytes><Technology><Teff cell><Toxic effect><Toxicities><Transfection><Translations><Transplant Recipients><Transplant Rejection><Transplantation><Transplantation Rejection><Treatment Cost><Treg><Vaccines><Validation><Virus Integration><Work><adoptive T cell transfer><adoptive T-cell therapy><adoptive cell therapy><adoptive cellular therapy><autoimmune condition><autoimmune disorder><autoimmunity disease><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cost><cyanine dye 5><cytokine><deliver mRNA><deliver messenger RNA><delivery system for mRNA><design><designing><developmental><effector T cell><experiment><experimental research><experimental study><experiments><fabrication cost><faces><facial><graft versus host disease><graft vs host disease><graft vs. host disease><heavy metal Pb><heavy metal lead><hepatic body system><hepatic organ system><host response><humanized mice><humanized mouse><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune system tolerance><immune unresponsiveness><immunogen><immunologic reactivity control><immunological paralysis><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><in vivo><kidney tx><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA delivery><malignancy><manufacture><manufacturing cost><messenger RNA delivery><nano particle><nano-sized particle><nanocarrier><nanoparticle><nanosized particle><nanovessel><neoplasm/cancer><nucleic acid delivery><pharmacologic><phase 2 study><phase II study><polymer><polymeric><pre-clinical><pre-clinical efficacy><pre-clinical study><preclinical><preclinical efficacy><preclinical study><regulatory T-cells><screening><screenings><site targeted delivery><social role><surface coating><targeted delivery><therapeutic T-cell platform><thymus derived lymphocyte><translation><transplant><transplant model><transplant patient><transplant therapy><transplant treatment><transplantation therapy><transplantation treatment><validations><viral integration>